Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
University Medical Center Groningen
Modality
radiopharmaceutical
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01832116CT.gov 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Digestive System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 89zr-mmot0530a (this asset) | University Medical Center Groningen | P1 | CC · 47 |
| Capecitabine | China Medical University, China | P3 | BB |
| Sorafenib | Sichuan Cancer Hospital and Research Institute | P3 | BB |
| Irinotecan | Pfizer | P3 | BB |
| Fluorouracilum | Janssen Research & Development, LLC | P3 | B |
| Acetylcysteine | German Cancer Research Center | P2 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Federico II University | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P1/2 | B |
| Linifanib | Abbott | P3 | B |
+41 more in the Digestive System Neoplasm cohort
Other indications for 89zr-mmot0530a
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Uterine Adnexa Cancer | — | P1 | CC · 47 |
| Digestive System Disorder | — | P1 | CC · 47 |
| Ovarian Disorder | — | P1 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 89zr-mmot0530a in Digestive System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/89zr-mmot0530a-digestive-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →